In 249 hospitalized patients with COVID-19, the prevalence of relative bradycardia was 60.6%, which did not significantly affect clinical outcomes such as ICU admission or death.
Observational (n=249)
No
Does relative bradycardia affect clinical outcomes in febrile patients with COVID-19?
Relative bradycardia is a common clinical sign in COVID-19 patients (60.6% prevalence) but is not associated with worse clinical outcomes.
Introduction: Relative bradycardia(RB) is a relatively low heart rate response to rise in body temperature that occurs in several infectious diseases and can be an important clinical sign. In previous case reports, RB was presented in some patients with Coronavirus disease 2019 (COVID-19) COVID-19.
Jung et al. (Sat,) conducted a observational in COVID-19 (n=249). COVID-19 was evaluated on Prevalence of relative bradycardia. In 249 hospitalized patients with COVID-19, the prevalence of relative bradycardia was 60.6%, which did not significantly affect clinical outcomes such as ICU admission or death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: